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Abstract: Background: Clostridium difficile infection (CDI) is the leading cause of infectious
nosocomial diarrhoea but the economic costs of CDI on healthcare systems in the US
remain uncertain.
Methods: We conducted a systematic search for published studies investigating the
direct medical cost associated with CDI hospital management in the past 10 years
(2005-2015) and included 42 studies to the final data analysis to estimate the financial
impact of CDI in the US. We also conducted a meta-analysis of all costs using Monte
Carlo simulation.
Results: The average cost for CDI case management and average CDI-attributable
costs per case were $42,316 (90% CI: $39,886, $44,765) and $21,448 (90% CI:
$21,152, $21,744) in 2015 US dollars. Hospital-onset CDI-attributable cost per case
was $34,157 (90% CI: $33,134, $35,180), which was 1.5 times the cost of community-
onset CDI ($20,095 [90% CI: $4991, $35,204]). The average and incremental length of
stay (LOS) for CDI inpatient treatment were 11.1 (90% CI: 8.7-13.6) days and 9.7 (90%
CI: 9.6-9.8) days respectively. Total annual CDI-attributable cost in the US is estimated
US$6.3 (Range: $1.9-$7.0) billion. Total annual CDI hospital management required
nearly 2.4 million days of inpatient stay.
Conclusions: This review indicates that CDI places a significant financial burden on the
US healthcare system. This review adds strong evidence to aid policy-making on
adequate resource allocation to CDI prevention and treatment in the US. Future
studies should focus on recurrent CDI, CDI in long-term care facilities and persons with
comorbidities and indirect cost from a societal perspective. Health-economic studies for
CDI preventive intervention are needed.
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Response to Reviewers: Responses to reviewers’ comments:
Reviewer #1: I wanted to congratulate the authors for their hard work in getting this
manuscript complete. The paper is well written and the study is well done. I have two
issues:
1. On page 8 line 9, it states that the control patients for the study are cancer patients
without CDI. I wanted to ask why cancer patients were chosen as controls.
Thank you very much for your question. I raised an example in the bracket, that some
studies used control groups with matching method. In those studies, similar patients
(matched with age, sex and health condition) without CDI were extracted from their
databases as compare group, and management cost for compare group (without CDI)
was also reported. Since these studies used appropriate matching methods, the results
should represent reliable estimates. In order to reduce confusions, I now change it to
“(e.g. matched patients without CDI)”.
2. The page 12, it states that the search results started with 2, 671 references and are
now done to 42 studies. Why were so many studies excluded?
Figure 3 showed the data extraction route in a PRISMA diagram. The reasons for
exclusion of most studies were listed in the box below. I have added another box
explaining the exclusion reasons for the full text articles, the content is as following:
Cost data reported for single management of C.Difficile (e.g. antibiotics only or fecal
microbiota transplant only) = 37
No primary cost data reported not for C.Difficile (e.g. decision modelling with one
treatment) = 10
Ineligible type of study design (e.g. review articles) = 6
Despite these two issues, I thought the study was well done and it is an excellent meta
analysis.
Reviewer #2: This manuscript is well developed and thought out.  It includes
comprehensive data review and analysis.
Comments:
1) The study categorized CDI outcomes in different ways - HO vs. CO, attributable vs.
related. Authors should state reasons and meanings behind each category.  Unless
authors strongly believe CDI related outcomes shed additional value, I would suggest
to consider focusing on attributable costs which are further categorized into HO vs. CO
CDI.
Thank you very much for your comments. Similar to your suggestion, HO-CDI and CO-
CDI were already presented in table 3, 4 and 5. As you can see, we carefully explained
the meanings behind HO and CO in Table 2 on page 15 and attributable vs related on
page 8 line 6-8. We believe that CDI attributable cost is the most important results that
we should estimate. These estimates should improve our understanding of the burden
of healthcare costs of C. diff disease in the US. As you are aware some studies only
reported related cost, and some studies reported related cost which can be used to
calculate attributable cost. Therefore, we believed related costs were as important as
attributable costs and should be included and presented both.
2)page 18, Line 8 through 11 should be presented in the Results session. Discussion
session should just focus on comparing and comments.
Agreed. I moved this part to the result section (page 37 line 9). Change this paragraph
into the following:
We systematically reviewed 42 published cost studies of CDI case management in the
past 10 years (2005-2015) and found a significant financial burden associated with CDI
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
in the US. The total CDI-attributable cost was US$6.3 billion, which is higher than
previously reported14,16,17. The mean cost for CDI-attributable hospitalized patients
per case was US$21,448, nearly half of the mean CDI-related inpatient cost.
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Dear Editor of the BMC Infectious Diseases, 
Thank you very much for your great news and we are truly grateful to yours and 
two reviewers’ critical comments and thoughtful suggestions to our manuscript 
‘Cost of hospital management of Clostridium difficile infection in United States – 
a meta-analysis and modelling study’.  
 
Based on these comments and suggestions, we carefully revised the original 
manuscript and the updated manuscript is attached with track changes. We also 
prepared point-by-point responses to the reviewers’ comments. Please find the 
responses below.  
 
We hope that these revisions are satisfactory and this version will be acceptable 
for publication in BMC Infectious Diseases.  
 
Thank you very much for your work on our paper, truly appreciate it.  
 
Best wishes, 
 
Shanshan Zhang on behalf of the authors 
 
Corresponding Author 
Dr. Shanshan Zhang   
PhD, DDS   
Usher Institute of Population, Health Sciences and Informatics  
University of Edinburgh   
Medical School, Teviot Place   
Edinburgh EH8 9AG, United Kindom   
Email: Shanshan.Zhang@ed.ac.uk 
cover letter －responses
Responses to reviewers’ comments: 
Reviewer #1: I wanted to congratulate the authors for their hard work in getting this manuscript 
complete. The paper is well written and the study is well done. I have two issues: 
1. On page 8 line 9, it states that the control patients for the study are cancer patients without 
CDI. I wanted to ask why cancer patients were chosen as controls. 
 
Thank you very much for your question. I raised an example in the bracket, that 
some studies used control groups with matching method. In those studies, similar 
patients (matched with age, sex and health condition) without CDI were extracted 
from their databases as compare group, and management cost for compare group 
(without CDI) was also reported. Since these studies used appropriate matching 
methods, the results should represent reliable estimates. In order to reduce 
confusions, I now change it to “(e.g. matched patients without CDI)”.  
   
2. The page 12, it states that the search results started with 2, 671 references and are now done 
to 42 studies. Why were so many studies excluded? 
 
Figure 3 showed the data extraction route in a PRISMA diagram. The reasons for 
exclusion of most studies were listed in the box below. I have added another box 
explaining the exclusion reasons for the full text articles, the content is as 
following: 
Cost data reported for single management of C.Difficile (e.g. antibiotics only or 
fecal microbiota transplant only) = 37  
No primary cost data reported not for C.Difficile (e.g. decision modelling with one 
treatment) = 10 
Ineligible type of study design (e.g. review articles) = 6 
 
Despite these two issues, I thought the study was well done and it is an excellent meta analysis. 
 
 
 
 
 Reviewer #2: This manuscript is well developed and thought out.  It includes comprehensive 
data review and analysis.  
Comments:  
1) The study categorized CDI outcomes in different ways - HO vs. CO, attributable vs. related. 
Authors should state reasons and meanings behind each category.  Unless authors strongly 
believe CDI related outcomes shed additional value, I would suggest to consider focusing on 
attributable costs which are further categorized into HO vs. CO CDI.   
 
Thank you very much for your comments. Similar to your suggestion, HO-CDI and 
CO-CDI were already presented in table 3, 4 and 5. As you can see, we carefully 
explained the meanings behind HO and CO in Table 2 on page 15 and attributable 
vs related on page 8 line 6-8. We believe that CDI attributable cost is the most 
important results that we should estimate. These estimates should improve our 
understanding of the burden of healthcare costs of C. diff disease in the US. As you 
are aware some studies only reported related cost, and some studies reported 
related cost which can be used to calculate attributable cost. Therefore, we 
believed related costs were as important as attributable costs and should be 
included and presented both.  
 
2)page 18, Line 8 through 11 should be presented in the Results session. Discussion session 
should just focus on comparing and comments. 
 
Agreed. I moved this part to the result section (page 37 line 9). Change this 
paragraph into the following: 
 
We systematically reviewed 42 published cost studies of CDI case management in 
the past 10 years (2005-2015) and found a significant financial burden associated 
with CDI in the US. The total CDI-attributable cost was US$6.3 billion, which is 
higher than previously reported14,16,17. The mean cost for CDI-attributable 
hospitalized patients per case was US$21,448, nearly half of the mean CDI-related 
inpatient cost. 
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Abstract:  1 
Background: Clostridium difficile infection (CDI) is the leading cause of 2 
infectious nosocomial diarrhoea but the economic costs of CDI on healthcare 3 
systems in the US remain uncertain.  4 
Methods: We conducted a systematic search for published studies 5 
investigating the direct medical cost associated with CDI hospital management 6 
in the past 10 years (2005-2015) and included 42 studies to the final data 7 
analysis to estimate the financial impact of CDI in the US. We also conducted 8 
a meta-analysis of all costs using Monte Carlo simulation.  9 
Results: The average cost for CDI case management and average 10 
CDI-attributable costs per case were $42,316 (90% CI: $39,886, $44,765) and 11 
$21,448 (90% CI: $21,152, $21,744) in 2015 US dollars. Hospital-onset 12 
CDI-attributable cost per case was $34,157 (90% CI: $33,134, $35,180), which 13 
was 1.5 times the cost of community-onset CDI ($20,095 [90% CI: $4991, 14 
$35,204]). The average and incremental length of stay (LOS) for CDI inpatient 15 
treatment were 11.1 (90% CI: 8.7-13.6) days and 9.7 (90% CI: 9.6-9.8) days 16 
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respectively. Total annual CDI-attributable cost in the US is estimated US$6.3 1 
(Range: $1.9-$7.0) billion. Total annual CDI hospital management required 2 
nearly 2.4 million days of inpatient stay.  3 
Conclusions: This review indicates that CDI places a significant financial 4 
burden on the US healthcare system. This review adds strong evidence to aid 5 
policy-making on adequate resource allocation to CDI prevention and 6 
treatment in the US. Future studies should focus on recurrent CDI, CDI in 7 
long-term care facilities and persons with comorbidities and indirect cost from 8 
a societal perspective. Health-economic studies for CDI preventive 9 
intervention are needed. 10 
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Background 1 
 2 
Clostridium difficile is the leading cause of infectious nosocomial diarrhoea in 3 
the United States (US)1 and the incidence and severity of C. difficile infection 4 
(CDI) are increasing2. CDI is associated with significant morbidity and mortality; 5 
it represents a large clinical burden due to the resultant diarrhoea and 6 
potentially life-threatening complications, including pseudomembranous colitis, 7 
toxic megacolon, perforations of the colon and sepsis.3-5 Up to 25% of patients 8 
suffer from a recurrence of CDI within 30 days of the initial infection. Patients 9 
at increased risk of CDI are those who are immuno-compromised, such as 10 
those with human immunodeficiency virus (HIV) or who are receiving 11 
chemotherapy6-8, patients receiving broad-spectrum antibiotic therapy9,10 or 12 
gastric acid suppression therapy9,11, patients aged over 65 years10, patients 13 
with serious underlying diseases12, patients in intensive care units (ICUs)10, or 14 
patients who have recently undergone non-surgical gastrointestinal 15 
procedures or those being tube-fed.10 16 
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 1 
CDI represents a significant economic burden on US healthcare systems. 2 
Infected patients have an increased length of hospital stay compared to 3 
uninfected patients, besides there are significant costs associated with treating 4 
recurrent infections. A few systematic reviews of cost-of-illness studies on CDI 5 
cost are available13-21. These reviews mainly listed the range of reported cost 6 
of their respective observation period or were limited by the small number of 7 
included studies or inadequate control for confounding factors. No 8 
meta-analysis of large number of cost data in the US has been conducted to 9 
date. The cost for patients discharged to long-term care facility (LTCF) and 10 
recurrent CDI management are understudied. The cost of case management 11 
and total financial burden of CDI treatment in the US is therefore 12 
underestimated and remains controversial.  13 
 14 
The aim of the current study is to conduct a systematic review and 15 
meta-analysis of currently available data to identify and quantify the financial 16 
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 6 
burden attributable to CDI, and to further estimate the total economic burden of 1 
CDI hospital management in the US.  2 
Methods 3 
 4 
Search Strategy 5 
English-language databases with online search tools were searched for to 6 
offer maximum coverage of the relevant literature: Medline (via the Ovid 7 
interface 1946 to July 2015); EMBASE (via the Ovid interface 1980 to July 8 
2015); The Centre for Review and Dissemination Library (incorporating the 9 
DARE, NHS EED, and NHS HTA databases); The Cochrane Library (via the 10 
Wiley Online Library) and Health Technology Assessment Database (1989 to 11 
July 2015).  12 
 13 
We supplemented our data by searching relevant published reports from: 14 
National epidemiological agencies, Google search for grey literature and hand 15 
searched the reference lists of the included studies. The general search 16 
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 7 
headings identified were: Clostridium difficile, economic, costs, cost analysis, 1 
health care costs, length of stay, hospitalization. Examples of the strategy for 2 
Medline and EMBASE are listed in Appendix 1.  3 
 4 
Study Selection 5 
All studies that reported novel direct medical cost and/or indirect costs related to CDI 6 
management were included. Review articles, comments, editorials, letters, studies of 7 
outbreaks, case reports, posters and articles reporting results from economic 8 
modelling of a single treatment measure (i.e. cost effectiveness of faecal 9 
transplantation) were excluded in the final analysis. All relevant publications from 10 
January 2005 to July 2015 were included in the search. We included the 11 
following healthcare settings: hospitals, long-term care facilities and 12 
community. Geographical scope covered the US. We did not apply any 13 
language restriction. Our predefined inclusion and exclusion criteria are shown in 14 
Appendix 2.  15 
 16 
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 8 
Data Extraction 1 
Two reviewers (SP, SZ) independently selected the included articles and 2 
extracted data. After combining their results, any discrepancies were solved by 3 
discussion with HN and MK.   4 
 5 
The primary outcomes were CDI-related costs (total costs of those with CDI 6 
and other comorbidities) and CDI-attributable costs (total costs of CDI 7 
management only, after controlling for the confounders). For studies with 8 
control groups (e.g. matched cancer patients without CDI), the CDI-attributable 9 
cost extracted was either the cost provided by the articles or calculated by 10 
reviewers using the CDI-related cost minus the treatment cost of control 11 
groups. The secondary outcome was resource utilization associated with CDI, 12 
i.e. CDI-related length of stay (LOS) in hospital and CDI-attributable LOS. The 13 
study characteristics of each article were extracted. These included basic 14 
publication information, study design, statistical methods, economic data 15 
reporting characteristics and population information.  16 
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 1 
When multiple cost data were presented in a study, we included only one cost 2 
estimate for each population subgroup as per the priority below:  3 
a. Matched data> Unmatched data 4 
b. Adjusted model results > Unadjusted model results 5 
c. Regression model results > Calculated difference  6 
d. Total cost/charges > Subgroup cost/charge (i.e. survivors, died) 7 
e. Median (Interquantile Range: IQR) > Mean (Standard Deviation, SD)  8 
 9 
All costs/charges data were inflated to 2015 US$ equivalent prices adjusted for 10 
the Consumer Price Index. If the price year was not reported, it was assumed 11 
to be the last year of the data collection period. In cases where charges were 12 
reported without cost-to-charge given, costs were estimated using a 13 
cost-to-charge ratio of 0.60, which is commonly used value in US health 14 
economic studies22. 15 
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Meta-analysis and Estimation of National Impact 1 
We carried out meta-analysis for cost studies following a Monte Carlo 2 
simulation approach, as reported by Jha et al23 and Zimlichman et al17, bearing 3 
in mind the heterogeneity of the included studies. For each subgroup of CDI, 4 
we synthesized the data and reported a point estimate and 90% confidence 5 
intervals (CIs) for the CDI-related cost, CDI-attributable cost and their 6 
respective LOS. For each included study, we simulated distribution with pooled 7 
results weighted by sample size. We fitted a triangular distribution for each of 8 
the included studies based on their reported measures of central tendency and 9 
dispersion, i.e. mean and 95% CI, median and IQR, or median and range. 10 
Then we simulated 100,000 sample draws from the modeled distribution of 11 
each study. At each iteration, we calculated the weighted average of all 12 
included studies. Finally, we reported the mean and 90%CI from the resulting 13 
distribution of the 100,000 weighted average of CDI. This approach facilitated 14 
the combination of cost data and eliminated the limitation of combining 15 
non-normally distributed data. Monte Carlo simulations were conducted using 16 
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the Monte Carlo simulation software @RISK, version 7.0 (Palisade Corp).  1 
 2 
We estimated the national financial impact of CDI on the US healthcare 3 
system, by determining the potential boundaries. The higher boundary was the 4 
total number of CDI cases in the US in 2011 extracted from Lessa et al24, while 5 
the lower boundary was the result from a meta-analysis to estimate the total 6 
burden of CDI cases in the US25 (For detailed results see Appendix 4). The 7 
total annual cost of CDI management was calculated multiplying the average 8 
cost of management per case of CDI, with the total number of CDI cases per 9 
year in the US (Figure 1). We assumed that all CDI cases received treatment 10 
in hospital. A point estimate of the final cost (with range) was reported based 11 
on a Monte Carlo simulation of 100,000 sample draws. 12 
 13 
Sensitivity Analysis  14 
We extracted the total number of CDI patients and CDI-attributable costs from 15 
previous studies25 and reviews17,26 to carry out a sensitivity analysis of our total 16 
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 12 
cost estimates.  1 
 2 
Quality Assessment 3 
The quality of the studies included was assessed mainly based on the 4 
complexity of the statistical method (figure 2). All studies were included in the 5 
final analyses.  6 
 7 
Results 8 
 9 
Search Results 10 
The search strategy identified 2,671 references from databases. Seven 11 
additional references were identified through other sources. After screening 12 
the titles, abstracts and relevant full texts (figure 3), a total of 42 studies were 13 
included in this review.  14 
 15 
Study Characteristics 16 
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The characteristics of the 42 included studies 27-68 are summarized in Table 1. 1 
Cost data collection periods ranged from 1997 to 2012. Most studies (n=27) 2 
used national level databases, with 17 used National Independent Sample 3 
(NIS) database and the remaining 10 studies extracted data from various 4 
national databases. Fifteen studies were conducted at state level, of which 6 5 
studies only collected data in single hospital. All studies reported cost in 6 
hospital level of care, no articles identified in LTCF and community. Nearly all 7 
identified references were retrospective hospital database studies (n=40) and 8 
only 1 study was a prospective observational study 29 and another study was a 9 
decision tree model48.  10 
 11 
Most studies (n=15) investigated economic outcomes in all age inpatients. 12 
Three studies reported cost data in children less than 20 years old. The 13 
mean/median age of the CDI patient groups ranged from 47.4 to 73.0 years. 14 
Other studies investigated complicated CDI in high-risk patient groups, such 15 
as those with major surgery (n=16), inflammatory bowel diseases (n=2), liver 16 
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or renal disease (n=4), elderly (n=2) and ICU patients (n=1). There was 1 1 
study each in non-surgical inpatients, sepsis inpatients and patients with 2 
prolonged acute mechanical ventilation. There was 1 study focusing only on 3 
recurrent CDI in the general population. 4 
 5 
The sample sizes of included studies ranged from 85 to 7,227,788, with a 6 
median sample size of 83,939. A total of 28.8 million inpatient hospital-days 7 
were analysed, of which 1.31 million inpatient hospital-days were CDI patients. 8 
The median sample size of CDI population was 2,938.  9 
 10 
The methods to identify CDI varied according to the type of CDI that was 11 
assessed in the study. CDI cases were identified either with laboratory test, i.e. 12 
positive C. diffcile toxin assay, or hospital discharge diagnosis of C. difficile 13 
(primary and/secondary) from administrative datasets using the International 14 
Classifications of diseases, Ninth, Clinical Modification, ICD-9-CM 008.45. 15 
Clinical diagnosis was also used in two studies.  16 
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 1 
CDI was classified in three types: Community-onset CDI (CO-CDI) requiring 2 
hospitalization, Hospital-onset CDI (HO-CDI) complicating other diseases, or 3 
both CDI (Table 2). Most of included studies considered HO-CDI (n = 23) or 4 
both CDI types (n = 17). Only four studies investigated CO-CDI only. However, 5 
subgroup data of CO-CDI is also available in studies that reported both CDI 6 
types.  7 
Table 2. Classification of CDI Cases by Setting of Acquisition 8 
Case definition  Criteria for classification 
CO-CDI - Discharge code ICD-9-CM 008.45 as Primary diagnosis 
HO-CDI 
- Discharge code ICD-9-CM 008.45 as secondary diagnosis, without a primary 
diagnosis of a CDI-related symptom (e.g. diarrhea) 
- Study population ≥ 48h of hospitalization 
- Symptom onset and/or positive laboratory assay at least ≥ 48h hospitalization 
Both CDI 
- No distinction of settings of acquisition  
- Discharge code ICD-9-CM 008.45 in any position  
Community-onset CDI: CO-CDI; Hospital-onset CDI: HO-CDI; ICD-9-CM: The International Classification 9 
of Diseases, Ninth Revision, Clinical Modification 10 
 11 
CDI Costs and LOS 12 
The mean CDI-attributable costs per case of CO-CDI were $20,085 (Range: 13 
$7,513- $29,662), lower than HO-CDI $34,149 (Range:$1,522- $122,318). 14 
HO-CDI showed a wider range within which the additional cost for CDI in the 15 
general population ranged from $6,893 to $90,202 and in high risk groups 16 
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ranged from $7,332 in congestive heart failure patients to $122,318 in renal 1 
impairment patients. The mean CDI-attributable LOS was 5.7 days (Range: 2 
2.1-33.4) for CO-CDI, 7.8 (Range:2.3-21.6) days for HO-CDI, and 13.6 3 
(Range: 2.2-16) days for both groups. Cost data and LOS for individual studies 4 
are presented in Tables 3 and 4.  5 
 6 
Using a Monte Carlo simulation, we generated point estimates and 90% CI for 7 
both cost and LOS; the meta-analysis results are shown in Table 5. The total 8 
cost of inpatient management of CDI-related disease was $42,316 (90%CI: 9 
$39,886-$44,765) per case, of which the total CDI-attributable cost was 10 
$21,448 (90%CI: 21,152-21,744) per case. For the inpatient management, the 11 
attributable cost for those HO-CDI was $34,157 (90%CI: $33,134-$35,180), 12 
which was 1.5 times as much as CO-CDI management $20,095 (90%CI: 13 
$4,991-$35,204).  14 
 15 
Similar patterns were observed in LOS data. The total CDI-related LOS was 16 
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11.1 days (90% CI: 8.7-13.6) and CDI-attributable LOS was 9.7 (90%CI: 1 
9.6-9.8). The HO-CDI patients had longer CDI-attributable LOS 9.7 days 2 
(90%CI: 9.7 - 9.7) than CO-CDI patients 5.7 days (90%CI: 4.1-7.3).   3 
 4 
CDI Annual National Impact Estimate 5 
The total burden of healthcare facility CDI in US was estimated 293,300 6 
(Range: 264,200- 453,000) cases per year.25 The total financial burden of CDI 7 
inpatient management was estimated to be US$6.3 (Range: $1.9 - $7.0) billion 8 
in 2015, which required 2.4 million days of hospital stay. The total CDI related 9 
disease management cost was nearly doubled at US$12.4 (Range: $3.7 - 10 
$14.4) billion in 2015 (Table 6). A sensitivity analysis showed that the total 11 
CDI-attributable cost ranged from $1.31 to $13.61, which covers our estimates 12 
(Appendix 5).   13 
 14 
Quality Assessment  15 
A summary of the quality assessment for statistical methods in included 16 
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studies is shown in Appendix 3. There were 13 studies of high quality, 21 1 
studies with medium quality and 8 low quality studies.  2 
 3 
Discussion  4 
 5 
We systematically reviewed 42 published cost studies of CDI case 6 
management in the past 10 years (2005-2015) and found a significant financial 7 
burden associated with CDI in the US. The total CDI-attributable cost was 8 
US$6.3 (Range: $1.9 - $7.0) billion, which is higher than previously reported 9 
(range US$1.1-4.8 billion)14,16,17. required about 2.4 million days of inpatient 10 
stay for CDI treatment. The mean cost for CDI-attributable hospitalized 11 
patients per case was US$21,448, nearly half of ($21,152- $21,744) and the 12 
mean CDI-related inpatient cost was US$42,316 ($39,886- $44,765).     13 
 14 
This review facilitated a meta-analysis of a large number of cost studies for 15 
costs related to CDI management and provided an uncertainty range. 16 
Formatted: Superscript
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Zimlichman et al17 applied this method to calculate CDI cost based on cost 1 
data from two cost-of-illness studies (O’Brian 200751 & Kyne 200269) and 2 
obtained a lower cost [2012US $11,285 ($9,118-$13,574)] than ours. Our 3 
review combined 100-point estimates and ranges from 42 individual studies, 4 
which provided more accurate and comprehensive data of the cost result. 5 
Despite the methodological heterogeneity in perspectives, treatment 6 
procedure and statistical analysis, each included study met our inclusion 7 
criteria, which were defined to identify studies that provided real world 8 
estimates of costs, therefore the combination of these data with uncertainty 9 
range represented a valuable and reliable summary of CDI-related cost.   10 
 11 
Furthermore, we evaluated hospital onset CDI and community onset CDI 12 
separately. We found that CDI complicating hospitalization cost more than CDI 13 
requiring hospitalization and the former had longer attributable hospital stay. 14 
Therefore, other factors, such as comorbidity, may contribute to infections and 15 
increase the difficulty of CDI treatment.  16 
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 1 
We estimated that the total cost attributable to CDI management in the US was 2 
nearly US$6.3 (Range: $1.9-$7.0) billion, which is similar to Dubberke and 3 
Olsen’s estimates at $4.8 billion14, but significantly higher than other studies 4 
(US$ 1.5 billion in Zimlichman et al17 and $1.1 billion in Ghantoji et al16). The 5 
later studies reported lower attributable cost per case based on a limited 6 
number of studies before 2005, which arguably is out-of-date. To compare with 7 
the latest review on global CDI cost (Nanwa et al26), this review identified 8 8 
additional studies with recent data. Nanwa et al26 found that the mean 9 
attributable CDI costs ranged from US$8,911 to US$30,049, which is similar to 10 
our results.    11 
 12 
In this study, we only assessed the quality of study emphasizing statistical 13 
methods and did not use the modified economic evaluation guideline as other 14 
COI systematic reviews. Cost and LOS estimation of healthcare-associated 15 
infections has the potential to be misleading if the confounders such as 16 
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patients’ comorbidities or daily severity of illness were not properly controlled 1 
for.  Using either the matching design or multivariable regression analysis 2 
allows to control known confounders and may, in part, address selection bias70. 3 
We found that whether advanced statistical methods were used and described 4 
was crucial for the assessment of data quality, which has not be fully captured 5 
by the existing quality assessment tool. Therefore in this study we assessed 6 
quality of included studies using this new method. Moreover, Nanwa et al26 has 7 
evaluated the methodological completeness of most included studies (34 out 8 
of 42); we agree with their recommendations regarding possible improvement 9 
of future cost-of-illness study. However, we need to bear in mind that cost 10 
effects or excess LOS are still likely to be overestimated if the interval to onset 11 
of HAI is not properly accounted for in the study design or analysis70.   12 
 13 
Our systematic review has some limitations. First, all included studies reported 14 
direct medical costs from hospital perspective, therefore indirect cost to 15 
patients and society and costs of additional care after hospital discharge, have 16 
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not been captured. No studies reported indirect cost (productivity loss due to 1 
work day losses) of patients or care-givers, and we failed to identify studies 2 
assessing cost of CDI in long-term care facilities, where about 9% of CDI 3 
patients were discharged to for an average of 24 days of after-care. This would 4 
result in an additional US$141 million burden on the healthcare system and 5 
society due to LTCF transfers14. Second, we did not separate primary CDI from 6 
recurrent CDI cost in our review because only two studies reported cost 7 
specifically to recurrent CDI $12,592 (Range: $9,752, $15,919)2. Moreover, we 8 
found it difficult to exactly match the CDI case definition in cost study (e.g. 9 
ICD10 Code primary diagnosis and secondary diagnosis) with the case 10 
definition in epidemiology studies (e.g. community onset, hospital onset), 11 
therefore we did not estimate CDI patients managed at outpatient and 12 
community settings due to lack of both epidemiology and economic data. The 13 
total costs of CDI management may be higher than our current estimate. 14 
Fourth, unlike other published reviews, we did not include cost studies from 15 
countries other than the US nor facilitate any international comparison. This 16 
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study initially aimed to identify cost-of-illness studies in North America, but we 1 
did not find any studies reporting cost data from Canada. This is likely because 2 
we restricted our search to English language databases. Therefore the cost of 3 
CDI management in Canada remains unknown. However, we did not apply 4 
any language restrictions to the current review.  5 
 6 
Effective prevention can reduce the burden of diseases. Strategies have been 7 
promoted such as appropriate use of antimicrobials, use of contact 8 
precautions and protective personal equipment to care for infected patients, 9 
effective cleaning and disinfection of equipment and the environment, and 10 
early recognition of disease as primary prophylaxis71. As CDI is an infectious 11 
disease, the population at risk would benefit from an effective vaccine, which is 12 
currently under development72,73.  13 
 14 
More cost of illness studies for recurrent CDI, or in LTCF, and indirect cost from 15 
a societal perspective are needed in the future. We would also recommend 16 
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that published studies report their methods and include point estimates with 1 
uncertainty range. Further economic studies for CDI preventive interventions 2 
are needed.   3 
 4 
Conclusion  5 
This review indicates that CDI places a significant financial burden on the US 6 
healthcare system. In addition, our findings suggest that the economic burden 7 
of CDI is greater than previously reported in the US. The total annual CDI 8 
attributable cost was estimated US$6.3 billion (Range: $1.9-$ 7.0) from 9 
hospital perspective, which required about 2.4 million days of inpatient stay for 10 
CDI treatment. This review provides strong evidence to aid policy-making on 11 
adequate resource allocation to CDI prevention and treatment in US.    12 
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Table 1. Overview of selected references that assessed economic burden attributable to CDI by type of CDI considered in the US 
 
ID
 Reference State, city 
Data 
collection 
period 
Type 
of CDI  
Population 
Sample 
size 
(Total) 
Sample 
size 
(CDI 
cases) 
Age of CDI patients  
Mean ± SD or 
(Range), years 
CDI definition 
(short) 
Quality 
assessment 
Statistical 
methodology 
Data source 
1 Ali 2012 National 2004-2008 Comp. 
Liver 
transplan
t 
193,714 5,159 >18 
ICD-9; 008.45 
(Primary 
Diagnosis-PD, 
Secondary 
Diagnosis-SD) 
Low 
No matching; 
no regression 
Nationwide Inpatient 
Sample (NIS) 
2 
Ananthakr
ishnan 
2008 
National 2003 Comp. IBD 124,570 2,804 
> 18    
CDI: 73*;  
CDI-IBD: 54*  
ICD-9; 008.45 
(PD) 
Medium 
No matching; 
regression 
NIS 
3 Arora 2011 Houston 2007-2008 Req. General 85 85 
Horn’s Index Score 
1&2: 64±19; Horn’s 
Index Score 3&4: 
65±15 
Toxin assay Low 
No matching; 
no regression 
St Luke’s Episcopal 
Hospital 
4 Bajaj 2010 National 
National: 
2005 
Tertiary:  
2002- 2006 
Both Cirrhosis 83,230 1,165 
CDI: 69±20; 
Cirrhosis-CDI: 61±15 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
NIS 
5 
Campbell 
2013 
National 2005 -2011 Comp. General NR 4,521 
Renal impairment 
72.9±13.4; 
Advanced Age: 
78.7±7.4; 
Cancer/BMT 
69.2±14.0; IBD 
61.2±18.3; Cabx 
exposure 61.2±14.8 
Toxin assay High 
Matching; 
regression 
Health Facts electronic 
health record (HER) 
database 
6 
Damle 
2014 
National 2008-2012 Comp. 
Colorectal 
surgery 
84,648 1,266 
>18  
63±17 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
University Health 
System Consortium 
Table 1, 3-6 Click here to download Table Table 1,3-6-cdiff cost reivew.docx 
database 
7 
Dubberke 
2008 
Missouri 2003-2003 Both 
Non- 
Surgical 
24,691 439 67(18-101)* Toxin assay High 
Matching; 
regression 
Barnes-Jewish Hospital 
Electronic record 
8 
Dubberke 
2014 
Missouri 2003-2009 Both 
Recurrent 
CDI 
3,958 421 >18 
Toxin assay or 
clinical 
diagnosis for 
recurrent CDI 
High 
Matching; 
regression 
Barnes-Jewish Hospital 
Electronic record 
9 
Egorova 
2015 
National 2000-2011 Comp. 
Vascular 
surgery 
NR 2,808 68.4 
ICD-9; 008.45 
(PD, SD) 
High 
Matching: 
regression 
NIS 
10 Flagg 2014 National 2004-2008 Comp. 
Cardiac 
surgery  
349,112 2,581 All age band 
ICD-9; 008.45 
(SD) 
High 
Matching: 
regression 
NIS 
11 
Fuller 
2009 
Maryland 
and 
California 
2007-2008 
for 
Maryland     
2005-2006 
for 
California  
Comp. General 3,760 3,760 - 
Clinical 
diagnosis 
Medium 
No matching; 
regression 
Health Services and 
Cost Review 
Commission, Maryland; 
The Office of 
State-wide Planning 
and Development, 
California 
12 
Glance 
2011 
National 
2005 – 
2006 
Comp. Trauma 149,648 768  69(45-82)* 
Clinical 
diagnosis 
Medium 
No matching; 
regression 
NIS 
13 Jiang 2013 
Rhode 
Islands 
2010-2011 Comp. General 225,999 6,053 
>18   
71.4±15.8 
ICD-9; 008.45 
(SD) 
Medium 
Matching; no 
regression 
Rhode Island’s 11 
acute-care hospitals 
14 Kim 2012 National 2001-2008 Comp. Cystectomy 10,856 153 
>18   
68.49 ±10.52 
ICD-9 ; 008.45 
(SD) 
Medium 
No matching; 
regression 
NIS 
15 Kuntz 2012 Colorado 2005-2008 Comp. General 3,067 3,067 
All age band, 
Outpatient 
62.8±19.4;  
Inpatient 69.9±16.3 
ICD-9 + toxin 
assay 
Medium 
No matching; 
regression 
Kaiser Permanente 
Colorado and Kaiser 
Permanente 
Northwest members  
16 Lagu 2014 
Massachu
setts, 
Boston 
one 
hospital 
2004-2010 Comp. Sepsis 218,915 2,348  70.9±15.1 
ICD-9; 008.45 
(PD, SD) + 
toxin assay 
Medium 
Matching; no 
regression 
Baystate Medical 
Center (Premier 
Healthcare Informatics 
database, a voluntary, 
fee-supported 
database) 
17 
Lameire 
2015 
National 2002-2009 Comp. 
Cardiac 
surgery  
512,217 421,294 
>40 
CABG 65.4±10.5 
VS 66.1±12.3 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
NIS 
18 
Lawrence 
2007 
Missouri 1997-1999 Both ICU 1,872 76 
Primary 68.9 
(34-93) 
Secondary 58.7 
(16-91) 
Toxin assay Medium 
No matching; 
regression 
A 19-bed medical ICU in 
a Midwestern tertiary 
care referral center. 
19 
Lesperanc
e 2011 
National 2004-2006 Comp. 
Elective 
colonic 
resections 
695,010 10,077 
>18  
All 69.8; 
Surgery-CDI 68.7 
ICD-9; 008.45 
(SD) 
Medium 
No matching; 
regression 
NIS 
20 Lipp 2012 New York 2007-2008 Comp. General 4,853,800 3,883 >17 
ICD-9; 008.45 
(SD) 
Medium 
No matching; 
regression 
- The SPARCS database 
- acute care 
non-federal hospitals 
in New York State 
21 
Maltenfor
t 2013 
National 2002-2010 Both 
Arthropla
sty 
NR NR All age band 
ICD-9; 008.45 
(PD, SD) 
Low 
No matching; 
no regression 
NIS 
22 
McGlone 
2012 
National 2008 Comp. General NR NR >65 
ICD-9; 008.45 
(SD) 
Low 
No matching; 
no regression 
Decision tree model 
23 
Nguyen 
2008 
National 1998-2004 Comp. IBD 527,187 2,372 47.4±0.2 
ICD-9; 008.45 
(secondary 
diagnosis) 
Medium 
No matching; 
regression 
NIS 
24 
Nylund 
2011 
National 
1997,2000, 
2003,2006 
Both Children 10,495,728 21,274 CDI 9.5±0.07(SEM) 
ICD-9; 008.45 
(PD, SD) 
High 
Matching: 
regression 
Healthcare Cost and 
Utilization Project 
Kids’Inpatient 
Database  
25 
O’Brien 
2007 
Massachu
setts  
1999-2003 Req. General 3,692 1,036 
Primary 70±17.6; 
Secondary 70±17.2 
ICD-9; 008.45 
(PD, SD) 
Low 
No matching; 
no regression 
Massachusetts 
hospital discharge data 
26 Pakyz 2011 National 2002-2007 Comp. General 30,071 10,857 CDI 61±17 
ICD-9; 008.45 
(SD) 
High 
Matching; 
regression 
University Health 
System Consorsoum 
(UHC) 
27 
Pant 
201253 
National 2009 Both 
Organ 
transplant 
(OT) 
244,955 6,451 
>18,  
OT-CDI 58±16*; 
CDI-only 73±22 * 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
NIS 
28 
Pant 2012 
(2)54 
National 2009 Both 
Renal 
disease 
184,139 5,151 
>18, 
ESRD+CDI 66±14 
CDI ONLY 70±17 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
NIS 
29 Pant 2013 National 2009 Both 
Children 
with IBD 
12,610 447 
<20,  
15.1±4.1 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
The Healthcare Cost 
and Utilization Project 
Kids’ Inpatient 
Database (HCUP-KID) 
30 Peery 2012 National From 2009 Req. General 110,533 110,533 All age band 
ICD-9; 008.45 
(PD) 
Low 
No matching; 
no regression 
National Ambulatory 
Medical Care Survey 
(NAMCS) and NIS 
31 
Quimbo 
2013 
National 2005-2010 Comp. 
High Risk 
subgroups  
21,177 26,620 
>18 
 67.5±17.6 
ICD-9; 008.45 
(PD, SD) 
High 
Matching: 
regression 
HealthCare Integrated 
Research Database 
32 Reed 2008 
Pennsylva
nia 
2002-2006 Comp. 
High Risk 
subgroups  
9,164 524 >17 
Hospital 
acquired 
CDAD 
Low 
No matching; 
no regression 
A large academic 
community hospital 
33 
Sammons 
2013 
National 2006-2011 Both Children 13,295 4,447 
1-18 
6 (2-13) * 
ICD-9; 008.45 
(PD, SD) + 
toxin assay 
High 
Matching; 
regression 
Free-standing 
children’s hospitals via 
the Paediatric Health 
Information System 
(PHIS) 
34 
Singal 
2014 
National 2007 Comp. Cirrhosis 89,673 1,444 All age band 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
NIS 
35 Song 2008 Maryland  2000 -2005 Both General 9,025 630 
>18  
unmatched 57.6 
matched 60.3 
Toxin assay High 
Matching; 
regression 
The Johns Hopkins 
hospital 
36 
Stewart 
2011 
National 2007 Both General 82,214 41,207 
All age band,  
70 
ICD-9; 008.45 
(PD, SD) 
Medium 
Matching; no 
regression 
NIS 
37 
Tabak 
2013 
Pennsylva
nia 
2007-2008 Comp. General 77,257 255 
All 64.8±17.6 
CDI 71.1±14.8 
Toxin assay High 
Matching; 
regression 
Six Pennsylvania 
hospitals via a clinical 
research database 
38 
VerLee 
2012 
Michigan 2002-2008 Req. General 517,413 517,413 All age band 
ICD-9; 008.45 
(PD) 
Low 
No matching; 
no regression 
All Michigan acute care 
hospitals 
39 Wang 2011 
Pennsylva
nia  
2005-2008 Both General 7,227,788 78,273 All age band 
ICD-9; 008.45 
(PD, SD) 
High 
Matching; 
regression 
The Pennsylvania 
Health Care Cost 
Containment Council 
(PHC4) database 
40 
Wilson 
2013 
National 2004-2008 Comp. Ileostomy 13,245 217 All age band 
ICD-9; 008.45 
(SD) 
High 
Matching; 
regression 
NIS 
41 
Zerey 
2007 
National 1999-2003 Both Surgical 1,553,597 8,113 
All age band  
70*m 
ICD-9; 008.45 
(PD, SD) 
Medium 
No matching; 
regression 
NIS 
42 
Zilberberg 
2009 
National 2005 Both 
Prolonged 
acute 
mechanical 
ventilation 
64,910 3,468 
>18   
66.7±15.9 
ICD-9; 008.45 
(PD, SD) 
Medium 
Matching; no 
regression 
NIS 
 
NR =Not Reported; IBD = Inflammatory bowel disease; LOS = Length of stay; ICU = Intensive Care Unit; Retrosp. = retrospective; Comp.= complicating; Req.= Requiring; Both= Requiring and complicating; PD=Primary Diagnosis; SD= Secondary 
Diagnosis; *=Median(Range) 
 
 
 
 
 
 
 
Table 3. CDI-attributable costs/charges and CDI-related management costs/charges  
Author,Year Population Outcome Statistic 
Incremental CDI-attributable Cost/Charges CDI–related Cost/Charges 
Note 
Sample 
size 
Attributabl
e cost 2015$ 
SD or 95%CI 
Sample 
Size 
CDI only 
cost 
2015$ 
SD, 95%CI or IQR 
CO-CDI Inpatient Cost 
Arora 2011 General Cost Median 85 25,436     85 25,436 
   
O'Brien 2007 General Cost Mean 4,015 14,736     4,015 14,736 
   
Peery 2012 General Cost Median 110,553 7,513     110,553 7,513 
   
VeerLee 2012 General Charges Mean 68,686 74,211 120,156   68,686 74,211 120,156 
  
Kuntz 2012 General Cost Mean 1,650 929 4,800   1,650 929 4,800 
 
Outpatient 
Kuntz 2012 General Cost Mean 1,316 11,877 35,923   1,316 11,877 35,923 
 
Inpatient 
O'Brien 2007 General Cost Median 1,036 7,263     1,036 7,263 
  
PD 
VeerLee 2012 General Charges Mean 17,413 27,463 40,484   17,413 27,463 40,484 
 
PD 
O'Brien 2007 General Cost Mean 3,327 16,946 34,655   3,327 16,946 
  
Rehospitalisation 
Sammons 2013 Children Cost Mean 2,060 19,993 15,973 24013 2,060 19,993 15,973 24,013 Community onset  
Ananthakrishnan 
2008 
IBD Charges Median 
    
44,400 16,864 
  
CDI only 
Pant 2013 IBD Charges Mean 12,610 12,761 6,868 18655 447 50,050 
  
CDI only 
Bajaj 2010 Cirrhosis Charges Mean 
    
58,220 70,309 
  
CDI only 
Quimbo 2013 CDI History Cost Mean 1,866 29,662 20,798 42300 933 51,863 36,641 73,411 CDI only 
Total numbers/Weighted Mean   224,617 20,085     314,141 23,322    
HO-CDI Inpatient Cost 
Fuller 2009 General Cost Coefficient 1,282 18,466 288   1,282 18,466 288 
 
Maryland, SD 
Fuller 2009 General Cost Coefficient 2,478 29,980 271   2,478 29,980 271 
 
California, SD 
Lipp 2012 General Cost Mean 3,826 32,050     3,826 32,050 
  
SD 
McGlone 2012 General Cost Median 54,046 10,016 8,547 12055 54,046 10,016 8,547 12,055 
SD Cost-hospital 
perspective-6day
s LOS 
McGlone 2012 General Cost Median 54,046 11,116 9,476 13366 54,046 11,116 9,476 13,366 10 days LOS 
McGlone 2012 General Cost Median 54,046 12,194 10,146 14896 54,046 12,194 10,146 14,896 14 days LOS 
O'Brien 2007 General Cost Median 2,656 6,630 
  
2,656 6,630 
  
SD 
VeerLee 2012 General Charges Mean 51,273 90,202 146,767 
 
51,273 90,202 146,767 
 
SD 
Jiang 2013 General Cost Median 7,264 11,689 
  
1,211 21,751 
   
Pakyz 2011 General Cost Mean 30,071 31,180 
  
10,857 64,732 
  
Unadjusted 
Pakyz 2011 General Cost Median 30,071 24,456 
  
10,857 39,598 22,400 88,537 Unadjusted 
Pakyz 2011 General Cost Mean 30,071 31,169 
  
10,857 64,000 63,541 64,458 Adjusted 
Tabak 2013 General Cost Mean 1,020 6,893 1,365 13617 255 22,992 12,222 42,470 
 
Campbell 2013 Age >= 65 Cost Mean 3,064 7,536 4,302 10771 3,064 48,932 67,727 
  
Quimbo 2013 Elderly Cost Mean 34,732 45,749 43,279 48359 10,933 83,004 78,548 87,713 
 
Sammons 2013 Children Cost Mean 2,414 99,012 84,626 113,398 2,414 99,012 84,626 113,398 
 
Ananthakrishnan 
2008 
IBD Charges Median 80,170 7,655 
  
2,804 24,623 
   
Ananthakrishnan 
2008 
IBD Charges Mean 80,170 14,368 9,467 19,270 - 
    
Campbell 2013 IBD Cost Mean 84 1,522 -14,932 11,888 84 40,194 44,845 
  
Quimbo 2013 IBD cost Mean 3,618 11,825 9,851 14,181 1,206 42,035 35,918 49,191 
 
Ananthakrishnan 
2008 
Ulcerative 
colitis (UC) 
Charges Median 
    
1,843 26,750 
   
Nguyen 2008 UC Charges Mean 43,645 14,749 
  
196 43,381 
  
Regression 
Ananthakrishnan 
2008 
Crohn's 
disease (CD) 
Charges Median 
    
961 22,738 
   
Nguyen 2008 CD Charges Mean 73,197 14,316 
  
329 41,453 
  
Regression 
Reed 2008 
Digestive 
disorders 
Charges Mean 2,394 3,670 
  
320 9,076 8,068 
  
Damle 2014 
Colorectal 
surgery  
Cost Median  84,648 14,644 13,700 15,589 1,266 21,309 38,218 
 
- 
Kim 2012 Cystectomy Cost Mean 10,856 25,014 
  
153 57,379 50,204 64,554 
 
Lesperance 2011 
Elective 
colonic 
resection 
Charges Mean 695,010 84,899 
  
10,077 158,401 
   
Reed 2008 
Major bowel 
procedures 
Charges Mean 1,035 25,476 
  
45 47,064 31,302 
  
Wilson 2013 Ileostomy Cost Mean 13,462 20,272 
  
217 35,076 
   
Wilson 2013 Ileostomy Cost Coefficient 13,462 17,513 14,106 20,921 
     
Egorova 2015 
Vascular 
surgery  
Cost Median  450,251 14,250 
  
4,708 36,847 22,912 62,903 
 
Flagg 2014 
Cardiac 
surgery  
Cost Median 5,160 19,524 
  
2,580 213,661 
  
Adjusted 
Flagg 2014 
Cardiac 
surgery  
Cost Median 349,122 38,320 
  
2,580 72,730 
  
Unadjusted 
Lemaire 2015 
Cardiac 
surgery  
Cost Median 421,294 35,968 
  
- 72,685 
  
CABG 
Lemaire 2015 
Cardiac 
surgery  
Cost Median 90,923 59,696 
  
- 106,141 
  
VS 
Reed 2008 
OR 
procedure for 
infectious 
/parasitic 
diseases 
Charges Mean 449 7,462 
  
32 35,524 25,498 
  
Glance 2011 Trauma Cost Median 149,656 24,131 
  
768 39,296 
   
Campbell 2013 Cabx  Cost Mean 1,641 18,567 10,448 26,687 1,641 78,948 99,739 
  
Quimbo 2013 Cabx Cost Mean 17,716 38,413 35,195 41,922 4,429 64,242 59,145 69,780 
 
Lagu 2014 Sepsis Cost Median 4,736 5,792 4,933 6,665 2,368 28,576 16,496 50,494 
 
Reed 2008 Septicaemia Charges Mean 1,211 9,141 
  
92 22,378 20,591 
  
Campbell 2013 
Renal 
impairment 
Cost Mean 3,236 5,024 1,118 8,928 3,236 50,586 72,180 
  
Quimbo 2013 RI Cost Mean 22,132 122,318 111,315 134,405 5,533 201,212 183,706 220,386 
 
Ali 2012 
Liver 
transplant 
Charges Mean 193,714 77,361 
  
5,159 158,038 
   
Singal 2014 Cirrhosis Charges Mean 89,673 23,310 
  
1,444 47,401 
   
Reed 2008 
Congestive 
Heart Failure 
Charges Mean 2,542 7,332 
  
35 14,738 13,841 
  
Quimbo 2013 
Immunocom
promised 
Cost Mean 14,344 33,632 30,151 37,516 3,586 73,612 66,048 82,041 
 
Campbell 2013 Cancer/BMT Cost Mean 782 687 -6,480 7,855 782 48,280 72,605 
  
Total numbers/Weighted mean     3,020,827 34,149     207,801 49,712       
Both CO-CDI and HO-CDI - Inpatient 
Dubberke 2014 Recurrent Cost Mean 3,958 12,163 
  
3,958 11,523 4,728 26,167 Total cost 
CDI  difference 
Dubberke 2014 
Recurrent 
CDI  
Cost Mean 3,958 12,692 9,752 15,919 
    
Adjusted 
Song 2008 General Cost Median 1,260 373 
  
630 30,305 
   
Stewart 2011 General Cost Mean 82,414 9,670 
  
41,207 26,790 
   
Wang 2011 General Cost Median 7,227,788 4,914 
  
78,273 12,081 
   
Nylund 2011 Children Charges Median 3,565 15,937 
  
3,565 25,549 
  
1997 
Nylund 2011 Children Charges Median 4,356 20,750 
  
4,356 31,858 
  
2000 
Nylund 2011 Children Charges Median 5,574 23,627 
  
5,574 33,625 11,348 97,822 2003 
Nylund 2011 Children Charges Median 7,779 23,362 
  
7,779 35,444 13,601 110,343 2006 
Sammons 2013 Children Cost Mean 698,616 51,304 44,746 57,969 698,616 51,304 44,746 57,969 
 
Dubberke 2008 Non-surgical Cost Median 24,691 11,749 
  
439 20,569 
  
Raw data 
Dubberke 2008 Non-surgical Charges Median 24,691 23,961 
  
439 42,154 
  
Raw data 
Dubberke 2008 Non-surgical Cost Mean 24,691 3,173 3078 3815 
    
Linear regression 
Dubberke 2008 Non-surgical Cost Median 24,691 4,190 
  
342 18,842 
  
Matched cases 
Dubberke 2008 Non-surgical Cost Mean 24,691 6,520 4910 8381 
    
Linear regression, 
180 days 
Dubberke 2008 Non-surgical Cost Median 24,691 9,284 
  
342 35,414 
  
Matched cases, 
180 days 
Zerey 2007 Surgical Charges Median 1,553,597 59,424 
  
8113 81,708 
   
Zerey 2007 Surgical Charges Coefficient 1,553,597 94,402 91589 97216 
    
Multivariate 
regression 
analysis 
Zilberberg 2009 
Prolonged 
acute 
mechanical 
Cost Median 64,910 48,065 
  
3468 190,188 107,689 333,290 Unadjusted 
ventilation 
(PAMV) 
Zilberberg 2009 PAMV Cost Mean 3,370 12,616 9186 16046 3468 91,039 71,306 
 
Adjusted  
Lawrence 2007 ICU Cost Median 1,872 7,043 
  
76 15,016 
  
ICU stay 
Lawrence 2007 ICU Cost Median 1,872 36,095 
  
76 60,723 
  
Entire hospital 
stay 
Bajaj 2010 Cirrhosis Charges Mean 83,230 49,460 
  
1165 96,678 
   
Maltenfort 2013 Arthroplasty Charges Median - 43,648 
  
- 84,877 52,498 142,827 
 
Pant 2012 
Organ 
transplant 
Charges Mean 49,198 77,246 73412 81080 63651 42,054 69,033 
  
Pant 2012 (2) Renal disease Charges Coefficient 184,139 69,679 68,338 71,020 59,793 87,982 
   
Pant 2013 IBD Charges Mean 12,610 39,453 32,470 46,436 
     
Total numbers/Weighted Mean     10,012,927 14,403     981,005 45,421       
Community-onset CDI=CO-CDI; Hospital-onset CDI= HO-CDI; PAMV=Prolonged acute mechanical ventilation; Cabx=Concomitant Antibiotic Use ; UC=Ulcerative colitis; CD= Crohn's 
disease; IBD= Inflammatory bowel disease; ICU= intensive care unit; CABG= coronary artery bypass grafting; VS= valvular surgery; BMT; PD=Primary Diagnosis; SD= Secondary Diagnosis; 
Calculated numbers were marked in Italic, attributable cost= cost of CDI group- cost of control non-CDI group.   
 
 
 
 
 
 
Table 4.  CDI-attributable LOS and CDI-related LOS  
Reference Population Statistic 
CDI VS NO CDI LOS (Days) CDI LOS (Days) 
Sample size Value SD or 95% CI Sample size Value SD or 95% CI 
CO-CDI Inpatient days  
Arora 2011 Horn's index 1&2 Mean 33 15.1 16.2   33 15.1 16.2   
Arora 2011 Horn's index 3&4 Mean 52 33.4 33.3   52 33.4 33.3   
Kuntz 2012 General outpatient Mean 1,650 10.0 17.0   1,650 10.0 17.0   
Kuntz 2012 General inpatient Mean 1,316 14.9 20.9   1,316 14.9 20.9   
O'Brien 2007 General Mean 4,015 6.4     4,015 6.4     
Pant 2013 IBD Coefficient 12,610 2.1 1.4 2.8   2.1 1.4 2.8 
Peery 2012 General Median 110,553 5.0     110,553 5.0     
Quimbo 2013 CDAD History Mean 1,866 2.9 2.4 3.6 933 8.9 7.2 11.0 
Sammons 2013 Children Median 2,060 5.6 4.5 6.6 2,060 6.0 4.0* 13.0* 
VeerLee 2012 General Mean 68,686 7.1 7.0   68,686 7.1 7.0   
Weighted Mean   202,841 5.7     189,298 5.9     
HO-CDI inpatient days 
Jiang 2013 General Median 7,264 8.0     1,211 13.0     
Lipp 2012 General Mean 3,826 12.0     3,826 12.0     
Pakyz 2011 General Mean 30,071 11.1     10,857 21.1 21.0 21.2 
Tabak 2013 General Median 1,020 2.3 0.9 3.8 255 12.0 9.0* 21.0* 
Wang 2013 General Median 7,227,788 7.0     78,273 6.0 4.0* 11.0* 
Campbell 2013 Age >= 65 Mean 3,064 3.0 1.4 4.6 3,064 21.3 25.3   
Quimbo 2013 Elderly Mean 34,732 7.8 7.5 8.1 10,933 18.8 18.2 19.5 
Sammons 2013 Children Median 2,414 21.6 19.3 23.9 2,414 23.0 12.0* 44.0* 
Ananthakrishnan 2008 IBD Median 80,170 3.0     2,804 7.0     
Campbell 2013 IBD Mean 84 3.0 -2.3 8.3 84 21.0 19.1   
Quimbo 2013 IBD Mean 3,618 3.3 2.9 3.7 1,206 12.8 11.6 14.2 
Nguyen 2008 Crohn's disease Mean 73,197 3.8     329 9.5     
Nguyen 2008 Ulcerative colitis Mean 43,645 3.2     196 9.9     
Reed 2008 Digestive disorders Mean 2,394 3.0     320 6.9 5.2   
Damle 2014 Colorectal surgery  Median  84,648 8.4 8.0 8.9 1,266 13.0 18.0   
Lesperance 2011 
Elective colonic 
resection 
Mean 695,010 11.7     10,077 22.6     
Reed 2008 Major bowel procedures Mean 1,035 10.0     45 20.9 11.3   
Wilson 2013 Ileostomy Mean 13,462 11.6     217 18.7     
Campbell 2013 Cabx exposure Mean 1,641 7.8 5.7 9.9 1,641 29.3 34.7   
Quimbo 2013 
Concomitant Antibiotic 
Use 
Mean 17,716 7.8 7.4 8.3 4,429 17.9 17.0 18.9 
Lagu 2014 Sepsis Mean 4,736 5.1 4.4 5.7 2,368 19.2     
Reed 2008 Septicemia Mean 1,211 5.0     92 10.7 7.6   
Egorova 2015 Vascular surgery  Median  450,251 6.7     4,708 15.0 9.0* 25.0* 
Flagg 2014 Cardiac surgery  Median  349,122 10.0     2,580 21.0     
Glance 2011 Trauma Median 149,656 10.0     768 16.0     
Lemaire 2015 Cardiac surgery (CABG) Median  421,294 12.0       19.0     
Lemaire 2015 Cardiac surgery (VS) Median  90,923 16.0       24.0     
Reed 2008 Congestive Heart Failure Mean 2,542 5.0     35 9.7 7.0   
Reed 2008 
OR procedure for 
infectious /parasitic 
diseases 
Mean 449 2.0     32 14.7 8.6   
Lawrence 2007 ICU Median         76 14.9 1.0+ 86.0+ 
Lawrence 2007 ICU Median         76 38.3 4.0+ 184.0+ 
Ali 2012 Liver transplant Mean 193,714 10.1     5,159 17.8     
Singal 2014 Cirrhosis Mean 89,673 7.5     1,444 13.9     
Quimbo 2013 Immunocompromised Mean 14,344 8.4 7.9 9.0 3,586 22.1 20.6 23.7 
Campbell 2013 Renal impairment Mean 3,236 4.0 2.9 5.1 3,236 22.7 28.2   
Quimbo 2013 Renal impairment Mean 22,132 17.3 16.4 18.3 5,533 37.5 35.5 39.6 
Campbell 2013 Cancer/BMT Mean 782 4.0 2.3 5.7 782 21.3 18.5   
Weighted Mean     10,120,864 7.8     168,892 13.5     
Both CO-CDI and HO-CDI inpatient cost 
Song 2008 General Median 1,260 4.0     630 22.0     
Stewart 2011 General Mean 82,414 5.1     41,207 13.0 14.0   
Nylund 2011 Children, 1997 Median 3,565 3.0     3,565 5.0 3.0* 14.0* 
Nylund 2011 Children, 2000 Median 4,356 4.0     4,356 6.0 3.0* 15.0* 
Nylund 2011 Children, 2003 Median 5,574 4.0     5,574 6.0 3.0* 14.0* 
Nylund 2011 Children, 2006 Median 7,779 4.0     7,779 6.0 3.0* 15.0* 
Sammons 2013 Children Median 698,616 12.2 10.6 13.8 698,616 10.0 5.0* 23.0* 
Bajaj 2010 Cirrhosis Mean 83,230 7.1     1,165 14.4     
Bajaj 2010 CDI only Mean         58,220 12.7     
Pant 2013 IBD Mean 12,610 2.2 1.5 2.8 447 8.2     
Dubberke 2008 Non-surgical Median 24,691 6.0     439 10.0 2. 0+ 87.0+ 
Lawrence 2007 ICU stay Median 1,872 3.1     76 6.1 1.0+ 86.0+ 
Lawrence 2007 Hospital stay Median 1,872 14.4     76 24.5 2.0+ 184.0+ 
Maltenfort 2013 Arthroplasty Median - 7.0     - 10.0 7.0* 17.0* 
Zerey 2007 Surgical Median 1,553,597 16.0 15.6 16.4 8,113 18.0     
Pant 2012 Organ transplant Median 49,198 9.6 9.3 9.9 63,651       
Pant 2012 (2) Renal disease Coefficient 184,139 9.4 9.2 9.5 59,793       
Zilberberg 2009 
Prolonged acute 
mechanical ventilation 
Median 3,370 6.1 4.9 7.4 3,468 25.0 15.0* 40.0* 
Weighted Mean   2,718,143 13.6     957,175 9.0     
Community-onset CDI= CO-CDI; Hospital-onset CDI= HO-CDI; PAMV=Prolonged acute mechanical ventilation; Cabx=Concomitant Antibiotic Use ; UC=Ulcerative colitis; CD= Crohn's 
disease; IBD= Inflammatory bowel disease; ICU= intensive care unit; CABG= coronary artery bypass grafting; VS= valvular surgery; BMT; PD=Primary Diagnosis; SD= Secondary Diagnosis; 
Calculated numbers were marked in Italic, attributable cost= cost of CDI group- cost of control non-CDI group.  *Q1-Q3  + Min-Max 
 Table 5. Meta analysis results of cost and LOS of CDI management  
CDI category 
CDI-attributable cost per case  
(2015 US$) 
CDI-related cost per case  
(2015 US$) 
CDI-attributable LOS per 
case (Days) 
CDI-related LOS per case 
(Days) 
 
Weighted 
Mean 
90%CI 
Weighted 
Mean 
90%CI 
Weighted 
Mean 
90%CI 
Weighted 
Mean 
90%CI 
CO-CDI 20,095 4,991 35,204 23,329 12,520 34,141 5.7 4.1 7.3 5.7 4.1 7.3 
HO-CDI 34,157 33,134 35,180 53,487 42,054 66,326 9.7 9.7 9.7 14.1 13.0 15.4 
Both CO-CDI and HO-CDI 17,650 17,292 18,009 46,000 42,502 49,533 10.4 9.7 11.0 11.8 7.1 17.6 
Overall inpatient 21,448 21,152 21,744 42,316 39,886 44,765 9.7 9.6 9.8 11.1 8.7 13.6 
CO-CDI= Community-onset CDI; HO-CDI= Hospital-onset CDI 
 
 
 
 
 
Table 6. Total cost of CDI management in US  
 
Total Number of HCF CDI Cases per year (2011)25 Mean 95%CI 
All population ≥2 years Median 293,300 264,200 322,500 
Adults ≥18 Upper boundary 288,900 261,100 316,700 
Adults ≥18 Lower boundary 133,887 91,780 195,402 
Cost per CDI case management (2015 US$) Weighted Mean 90%CI 
Overall CDI-attributable cost 21,448 21,152 21,744 
Overall CDI-related cost 42,316 39,886 44,765 
Total cost per year (in Billions, 2015 US$) Weighted Mean Range 
Total CDI-attributable cost per year 6.29 1.94 7.01 
Mean 6.29 5.59 7.01 
Upper boundary 6.19 5.52 6.88 
Lower boundary 2.87 1.94 4.25 
Total CDI-related cost per year 12.41 3.66 14.44 
Mean 12.41 5.59 14.44 
Upper boundary 12.25 10.41 14.18 
Lower boundary 5.67 3.66 8.75 
HCF-Healthcare Facility ; CDI- Clostridium difficile infection; CI- Confidence intervals.   
 
  
× ＝ 
Overall cost per 
CDI case 
management  
Total annual cost 
of CDI 
management 
Total number of 
CDI cases per 
year 
Figure 1: Formula for total annual cost calculation 
 
Figures 1 and 2 Click here to download Figure INFD-D-16-00526 Figures 1 and 2.pdf 
Figure 2. Quality Assessment Method: 
When a study used matching methods combined with adjusted regression(s), 
the statistical method was judged of high quality 
When a study used either matching methods or adjusted regression(s), the 
statistical method was judged of medium quality 
When a study used neither matching methods nor adjusted regression(s), the 
statistical method was judged of low quality 
Figure	3:	PRISMA	diagram	of	economic	burden	search	of	C.	difficile 
Id
en
tif
ica
tio
n 
Sc
re
en
in
g 
El
ig
ib
ili
ty
 
In
clu
de
d 
Records	excluded	 	
(n	=	2,028) 
Studies	included	in	the	review	
(n	=	42)	
)
Full-text	articles	assessed	for	
eligibility	 	
(n	=	88)	  
Titles	and	abstracts	screened	 	
(n	=	2,116) 
Full-text	articles	excluded	
(n	=	53)	  
	
Records	after	duplicates	
removed	 	
(n	=	2,116)	  
Records	identified	through	database	searching 
(n	=	2,671) 
Additional	records	identified	
through	other	sources	 	
(n	=	7) 
Main	reasons	for	exclusion	(2028)	
l No	cost	data	for	primary	outcome	of	interest	=	1191	
l Data	reported	not	for	C.	Difficile	=	758	
l Ineligible	 type	 of	 publications	 or	 study	 design	 (e.g.	 letters,	 comments,	 posters,	
abstracts)	=	53	
l No	primary	cost	data	(e.g.	review	articles,	economic	modelling	of	one	treatment)	=	26	
	
Main	reasons	for	exclusion	of	full	text	articles	(53)	 	
l Cost	data	reported	for	single	management	of	C.Difficile	(e.g.	antibiotics	only)	=	37	  
l No	primary	cost	data	reported	not	for	C.Difficile	=	10 
l Ineligible	type	of	study	design	(e.g.	review	articles)	=	6	
	
Figure 3 Click here to download Figure Revised-figure 3- Cdiff cost
review.pdf
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